Safety and Efficacy of Ellacor® Micro-coring® Following Best Practices on Technique and Post-Procedural Care

Conditions

• Best Practices
• Ellacor
• Ellacor Post Care
• Micro-coring Post Care

Eligibility Criteria

Sex

ALL

Age

45 Years - 65 Years

Healthy Volunteers

Accepted

Interventions

• ellacor Micro-Coring Technology — DEVICE
  ellacor will be used to treat moderate-severe wrinkles in the mid to lower face in subjects aged between 45-65.

Study Details

Since its inception of being marketed in the United States in 2021, physicians have used various post procedure skin care regimen to facilitate recovery. This study aims to examine the use of three post care products in five skin care regimens

Key Dates

Start date

Nov 26, 2025

Status verified

Nov 2025

Primary completion

May 31, 2026

Completion

Jun 30, 2026

Study Design

Enrollment

24 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Arms

• Active Comparator: Regenerating Skin Nectar (by Alastin) + Tegaderm
  Alastin to be applied post procedure followed up Tegaderm. Tegaderm will be left on for 12 hours. Alastin will be applied twice daily for the duration of the study
• Active Comparator: Kerra+ Recovery Cream (by Quthero) + Tegaderm
  Patients will receive Kerra+ post procedure followed by Tegaderm. The Tegaderm is removed after 12 hours. Kerra+ will be applied twice daily for the duration of the study.
• Active Comparator: Ariessence Platelet-Derived Growth Factor (PDGF) solution +Alastin + Tegaderm
  Patients will receive PDGF immediately post procedure followed by Alastin followed by Tegaderm. The Tegaderm will be removed after 12 hours and the Alastin will continue to be applied twice daily for the duration of the study
• Active Comparator: Ariessence PDGF solution + Kerra+ Recovery Cream + Tegaderm
  Patients will receive PDGF immediately post procedure followed by Kerra+ followed by Tegaderm. The Tegaderm will be removed after 12 hours and the Kerra+ will continue to be applied twice daily for the duration of the study
• Active Comparator: Tegaderm Only
  Patient will only receive Tegaderm for post-care

Primary Outcome Measure

Global Aesthetic Improvement Scale (GAIS) [ Time Frame: GAIS Assessment will be performed under a timeframe of 90 days ]

Locations (2)

Find similar trials in Miami, FL